Trade Alert: The Chief Financial Officer Of Harpoon Therapeutics, Inc. (NASDAQ:HARP), Georgia Erbez, Has Just Spent US$94k Buying Shares
Even if it's not a huge purchase, we think it was good to see that Georgia Erbez, the Chief Financial Officer of Harpoon Therapeutics, Inc. (NASDAQ:HARP) recently shelled out US$94k to buy stock, at US$14.09 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 14%.
View our latest analysis for Harpoon Therapeutics
The Last 12 Months Of Insider Transactions At Harpoon Therapeutics
Notably, that recent purchase by Georgia Erbez is the biggest insider purchase of Harpoon Therapeutics shares that we've seen in the last year. That implies that an insider found the current price of US$14.62 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Harpoon Therapeutics insiders decided to buy shares at close to current prices.
While Harpoon Therapeutics insiders bought shares last year, they didn't sell. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Harpoon Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership of Harpoon Therapeutics
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Harpoon Therapeutics insiders own 1.4% of the company, worth about US$5.1m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
What Might The Insider Transactions At Harpoon Therapeutics Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Harpoon Therapeutics stock. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Harpoon Therapeutics.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
